Has AOD-9604 completed any human clinical trials?

No. AOD-9604 has zero completed clinical trials in human subjects. All available data comes from in-vitro cellular studies and animal models. This absence of human evidence is a primary reason the compound remains unregulated and in research status.

What does Evidence Grade C mean for AOD-9604?

Grade C indicates preclinical evidence of biological activity exists (laboratory studies show mechanism), but human clinical evidence is absent or minimal. It reflects promise at the molecular level but insufficient data to support therapeutic claims in people. This grade justifies continued research but not clinical deployment.

Why is AOD-9604 not approved by the FDA or EMA?

Regulatory approval requires both preclinical data AND human clinical evidence of safety and efficacy. AOD-9604 has the former but lacks the latter. No manufacturer has initiated formal clinical development programmes or submitted regulatory applications, likely due to the scientific uncertainty and investment required.

How does AOD-9604 research compare to other peptide compounds?

AOD-9604 lags behind compounds like Abaloparatide, which has completed Phase III trials, and even earlier-stage compounds like ACE-031 and ARA-290, which have human trial data. AOD-9604 remains at the preclinical stage with no initiated clinical evaluation.

What key research gaps exist for AOD-9604?

Major gaps include: no human pharmacokinetics, no safety or toxicity data in people, no dose-response studies, and no efficacy evidence in any population. Essentially, every aspect of translating from laboratory to clinical use remains unknown.

AOD-9604 Research Evidence: Clinical Trial Data & Studies

AOD-9604 is a research compound derived from human growth hormone (hGH) fragment 176-191, designed to target fat metabolism pathways. Currently classified as an investigational compound with no approved clinical use, AOD-9604 sits at the centre of growing scientific interest but limited human trial data. The evidence grade is C—meaning preclinical and early-stage research exists, but robust human clinical evidence remains sparse. Understanding what research actually shows, versus what remains speculative, is critical for anyone evaluating this compound's potential role in metabolic research.

The AOD-9604 Compound Profile

AOD-9604 emerged from research into growth hormone and its metabolic effects. Unlike full-length hGH, this fragment isolate was hypothesised to retain lipolytic (fat-burning) properties while avoiding some of the systemic effects associated with complete growth hormone signalling. The compound has been the subject of multiple laboratory and animal model investigations, establishing a foundation for understanding its mechanism, but human data remains limited.

The compound classification as a research compound means it has not undergone full regulatory approval in the US, EU, Canada, or other major markets. This has significant implications for the quality and breadth of evidence available.

Clinical Trial Landscape

One of the most striking facts about AOD-9604 is the absence of completed Phase III clinical trials. A 2009 PubMed-indexed systematic review of growth hormone fragment research noted early-stage interest in hGH fragment 176-191, but highlighted the paucity of human randomised controlled trials. To date, there are zero registered clinical trials in the primary ClinicalTrials.gov database specifically designed to evaluate AOD-9604 safety and efficacy in human subjects.

This absence is not trivial. It means:

No Phase I, II, or III trial data on human safety profiles
No dose-escalation studies in humans
No pharmacokinetic or bioavailability data in clinical populations
No long-term follow-up data

By contrast, other peptide research compounds like Alexamorelin and Amycretin have active clinical trial programmes tracking their development. AOD-9604 does not.

Preclinical and In Vitro Research

The scientific foundation for AOD-9604 rests primarily on preclinical work. In-vitro studies demonstrated that the fragment exhibits lipolytic activity in isolated adipocyte cultures, suggesting a mechanism distinct from full-length growth hormone signalling. Research indicated the fragment may act via a specific membrane receptor pathway rather than the classical GH receptor.

Animal model research has been cited in the published literature, with some studies suggesting metabolic effects on body composition in rodent systems. However, animal models do not reliably predict human response—a fact that underscores why human trials are considered the gold standard.

Evidence Grade: C Classification Explained

AOD-9604 carries an Evidence Grade C designation. This reflects:

Limited human clinical data (zero completed trials)
Preclinical evidence of biological activity
Mechanistic plausibility based on receptor and cellular studies
Insufficient data to support therapeutic claims in any population

Grade C is not a "fail"—it acknowledges that the compound has shown scientific promise in controlled laboratory settings. But it also signals that human-level evidence is absent. For comparison, approved compounds like Abaloparatide achieved Grade A/B status through multiple Phase II and Phase III randomised controlled trials with published safety and efficacy outcomes.

What Research Actually Shows

In Vitro and Cellular Data

A landmark in-vitro study examined AOD-9604's receptor selectivity and lipolytic signalling mechanisms. The research demonstrated that the peptide fragment could activate adipocyte lipolysis via a receptor mechanism that appeared distinct from classical GH signalling pathways. This finding was significant because it suggested a potential metabolic target without triggering systemic GH-like effects.

Animal Model Observations

Preclinical rodent studies cited in the literature indicated changes in body composition metrics following exposure to the compound. However, a comprehensive review of growth hormone fragment research published in a peer-reviewed journal noted that these early findings required validation in human subjects before clinical relevance could be established.

Human Data Gaps

No published human clinical trials exist. This is the most critical limitation. Without human pharmacokinetic data, dose-response relationships, safety profiles, or efficacy outcomes, claims about the compound's effects in people remain speculative.

Where Research Gaps Remain

The evidence landscape for AOD-9604 is characterised by significant gaps:

Pharmacokinetics in Humans: No data on absorption, distribution, metabolism, or clearance. Unknown bioavailability after different routes of administration.

Safety Profile: No systematic evaluation of adverse events, contraindications, or drug interactions in human subjects. Long-term safety is entirely unknown.

Efficacy in Any Population: Zero randomised controlled trials establishing efficacy for any indication. No dose-response data.

Mechanism in Humans: While cellular studies are informative, the compound's actual mechanism of action in living human organisms remains unstudied.

Comparison to Alternatives: No head-to-head trials versus other metabolic interventions, making relative benefit unclear.

These gaps explain why AOD-9604 remains in the research compound category rather than advancing to clinical development or regulatory approval pathways.

Regulatory Status and Its Implications

AOD-9604 is not approved by the FDA, EMA, or Health Canada. This means:

No manufacturer has submitted an Investigational New Drug (IND) application to initiate formal clinical trials
No drug manufacturer is conducting regulated clinical development
The compound is not available through licensed pharmaceutical channels

The regulatory absence is a direct consequence of insufficient evidence. Regulators require preclinical data (which exists) plus human clinical evidence (which does not) before approving a novel compound for therapeutic use.

Comparison to Related Research Peptides

To contextualise AOD-9604's evidence position, consider compounds at different stages of development:

ACE-031 (also a research compound) has undergone early human studies exploring muscle-wasting indications, placing it slightly further along the translational pathway. ARA-290 has progressed through multiple Phase II trials in specific patient populations, generating human safety and preliminary efficacy data. By contrast, AOD-9604 has not yet initiated formal clinical evaluation.

What This Means for Research Interest

The absence of human trial data does not mean AOD-9604 lacks scientific credibility at the preclinical level. The in-vitro mechanism studies are legitimate science. But it does mean:

Preclinical ≠ Clinical: Laboratory evidence of biological activity does not predict human outcomes.
No Safety Data Exists: The compound has never been systematically evaluated in people.
No Efficacy Claims Are Supported: Any claim that AOD-9604 produces specific effects in humans lacks evidentiary support.
Unknown Optimal Use: Without human studies, dose, frequency, patient selection, and duration are all unknown.

For researchers and institutions considering engagement with AOD-9604, this reality shapes appropriate expectations and ethical boundaries. Preclinical research can continue, but any human-facing application would require formal clinical trial infrastructure and regulatory oversight.

Future Research Directions

If AOD-9604 were to progress clinically, the pathway would likely include:

Phase I safety and pharmacokinetic studies in healthy volunteers
Phase II dose-escalation and preliminary efficacy studies in a defined patient population
Phase III randomised controlled trials versus placebo and/or active comparators
Long-term follow-up to assess durability and safety

None of these steps have been initiated or completed. The compound remains firmly in the preclinical research domain.

AOD-9604 Research Evidence: What the Science Shows So Far